Get the Stockscreener App
0.528
0.21%
0.0011
Gri Bio Inc stock is traded at $0.528, with a volume of 1.50M.
It is up +0.21% in the last 24 hours and down -71.76% over the past month.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
See More
Previous Close:
$0.5269
Open:
$0.545
24h Volume:
1.50M
Relative Volume:
1.03
Market Cap:
$1.73M
Revenue:
-
Net Income/Loss:
$-8.26M
P/E Ratio:
-0.00985
EPS:
-53.609
Net Cash Flow:
$-12.17M
1W Performance:
-74.37%
1M Performance:
-71.76%
6M Performance:
-62.29%
1Y Performance:
-96.33%
1-Day Range:
$0.51
$0.56
1-Week Range:
$0.5001
$1.88
52-Week Range:
$0.5001
$15.64
Gri Bio Inc Stock (GRI) Company Profile
Name
Gri Bio Inc
Sector
Industry
Phone
(619) 400-1171
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA
Compare GRI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
0.528 | 1.72M | 0 | -8.26M | -12.17M | -53.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | H.C. Wainwright | Buy |
Gri Bio Inc Stock (GRI) Latest News
GRI Bio closes $8 million public offering of common stock and warrants - Investing.com Nigeria
GRI Bio closes $8 million public offering of common stock and warrants By Investing.com - Investing.com South Africa
GRI Bio Announces Closing of $8.0 Million Public Offering - GlobeNewswire
GRI Bio Launches $6.7 Million Public Offering - TipRanks
GRI Bio prices $8 million public offering at $0.75 per share - Investing.com
GRI Bio announces pricing of $8M public offering - MSN
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
GRI Bio (NASDAQ: GRI) prices $8,000,000 offering of 10,666,667 shares at $0.75 - Stock Titan
What's Going On With GRI Bio Stock Thursday?GRI Bio (NASDAQ:GRI) - Benzinga
GRI Bio’s IPF drug shows positive Phase 2a results with improved lung function - Investing.com Nigeria
GRI Bio Meets Key Goals In Phase 2 Trial Of GRI-0621 For Idiopathic Pulmonary Fibrosis - Nasdaq
GRI Bio Announces Positive Phase 2a Trial Results - TipRanks
GRI Bio, Inc. Announces Positive Phase 2a Trial Results for GRI-0621 - TradingView
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewswire
A new trading data show Milestone Pharmaceuticals Inc (MIST) is showing positive returns. - Setenews
Financial Contrast: CalciMedica (NASDAQ:CALC) and GRI Bio (NASDAQ:GRI) - Defense World
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.45% - Investing.com UK
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.45% - Investing.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
GRI Bio Reports Positive Phase 2a Trial Results - TipRanks
GRI Bio Increceives topline data from phase 2a trial for idiopathic pulmonary fibrosisSEC filing - marketscreener.com
GRI Bio Reports Positive Phase 2a Trial Results for IPF Treatment - TradingView
Ascendiant Capital Maintains GRI Bio (GRI) Buy Recommendation - Nasdaq
Ascendiant Capital Raises Price Target for GRI to $36.00 | GRI S - GuruFocus
Why GRI Bio Inc. stock is seen as undervaluedSell Signal & Weekly Return Optimization Alerts - Newser
JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025 - The Herald-Mail
GRI Bio receives Nasdaq notice for non-compliance with equity listing rule - Investing.com Australia
GRI Bio (GRI) Stock Analysis Report | Financials & Insights - Benzinga
GRI Bio Inc. (GRI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What insider trading reveals about GRI Bio Inc. stockWeekly Gains Summary & Long-Term Safe Investment Ideas - BỘ NỘI VỤ
Stop Loss: What sentiment indicators say about GRI Bio Inc. stock2025 Retail Activity & Long-Term Growth Portfolio Plans - moha.gov.vn
Buy Signal: What insider trading reveals about GRI Bio Inc. stock2025 Technical Overview & Low Risk Profit Maximizing Plans - moha.gov.vn
This trade activity should not be overlooked: GRI Bio Inc (GRI) - Setenews
Wall Street analysts’ outlook for Moolec Science SA (MLEC) - Setenews
A better buy-in window may exist right now for Movano Inc (MOVE) - Setenews
GRI Bio Inc Stock Analysis and ForecastRisk Mitigation Techniques & Rapid Capital Appreciation - earlytimes.in
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ('IPF') - ADVFN
GRI Stock Price and Chart — NASDAQ:GRI - TradingView
The growth track for GRI Bio Inc (GRI) has changed recently - Setenews
What technical charts say about GRI Bio Inc. stock2025 Price Action Summary & Weekly Setup with High ROI Potential - newser.com
How GRI Bio Inc. stock benefits from strong dollarShare Buyback & Free Daily Entry Point Trade Alerts - newser.com
GRI Bio Inc. stock daily chart insightsWeekly Investment Report & Low Drawdown Momentum Ideas - newser.com
Visual analytics tools that track GRI Bio Inc. performanceBond Market & Reliable Price Breakout Signals - newser.com
How supply chain issues affect GRI Bio Inc. stock2025 Top Decliners & Daily Profit Focused Screening - newser.com
Will GRI Bio Inc. stock see insider buyingMarket Growth Summary & Free High Accuracy Swing Entry Alerts - newser.com
Gri Bio Inc Stock (GRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):